New hope for tough tumors: experimental drug SB17170 enters human testing
NCT ID NCT05522868
First seen Nov 20, 2025 · Last updated May 11, 2026 · Updated 20 times
Summary
This early-phase trial tests a new drug, SB17170, in about 50 adults with advanced solid tumors that have stopped responding to standard care. The main goals are to find the safest dose and check for side effects. Researchers will also measure how the drug moves through the body and look for early signs that it might shrink tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Asan Medical Center
NOT_YET_RECRUITINGSeoul, South Korea
Contact
-
Seoul National University Hospital
NOT_YET_RECRUITINGSeoul, South Korea
Contact
-
Severance Hospital
RECRUITINGSeoul, South Korea
Contact
Conditions
Explore the condition pages connected to this study.